ALNY250117P180000
- 0.55
- 0.000.00%
Alnylam Pharmaceuticals Newsroom
Bernstein Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Raises Target Price to $310
Alnylam Pharmaceuticals Is Maintained at Outperform by Bernstein
Alnylam Pharmaceuticals Analyst Ratings
Express News | Alnylam Pharmaceuticals Inc : Bernstein Cuts Target Price to $310 From $314
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years
Annual Review | The most powerful month saw a threefold increase! Looking back at the monthly explosive rise of US stocks in 2024, AI and Trump Trade swept the whole year, with three Stocks making the list twice.
The US stock market continues to rise in 2024, mainly due to two significant trends: the tech stock frenzy driven by the AI boom and Trump's return to the White House.
Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?
How Is The Market Feeling About Alnylam Pharmaceuticals?
Express News | Alnylam Pharmaceuticals: Givlaari Now Widely Reimbursed in Canada for Treatment of Acute Hepatic Porphyria in Adults
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): When Will It Breakeven?
4 Biotech Stocks Most Wall Street Analysts Are Bullish About
Leerink Partners Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating
Piper Sandler Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Raises Target Price to $304
The Nasdaq 100 is about to adjust, and these 11 companies may see a 50% increase in upside potential.
As the annual adjustment of the NASDAQ 100 Index approaches, a group of potential stocks is preparing to make their debut. This adjustment not only brings prestige to these companies but may also trigger a large-scale inflow of capital, further driving up stock prices.
Alnylam Pharmaceuticals Insider Sold Shares Worth $439,760, According to a Recent SEC Filing
Palantir, MicroStrategy Could Be Added to Nasdaq 100 Friday. Moderna, Super Micro Could Be Dropped.
Vir Gets FDA Breakthrough Therapy Status for Two Drugs
Antisense & RNAi Therapeutics Market Report 2024, Featuring Profiles of Alnylam Pharmaceuticals, Arbutus Biopharma, Benitec Biopharma, GSK, Ionis Pharmaceuticals, Sanofi, Sarepta Therapeutics & More - ResearchAndMarkets.com
MicroStrategy Stock Could Get Added to the Nasdaq 100 Because of a Quirk